[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"memory-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:memory-loss":297},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,77,105,137,157,188,211,235,261],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100506654",false,"NCT05877196","A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses","Precision Medicine in Alzheimer's Disease: A SMART Trial of Adaptive Exercises and Their Mechanisms of Action Using AT(N) Biomarkers to Optimize Aerobic-Fitness Responses (The FIT-AD SMART Trial)","SMART","Inclusion Criteria:\n\nParticipants:\n\n* Clinical diagnosis of MCI or probable and possible mild AD dementia according to 2011 Alzheimer's association-NIA criteria.\n* Community-dwelling, e.g., homes and assisted living\n* Age 65 years and older\n* Medical clearance from PCP or cardiovascular provider\n* Have a qualified study partner\n* Agree to the blood draws\n* Verified MRI safety\n\nStudy Partner:\n\n* Age 18 or older\n* Contact with participant ≥ 2 times per week for ≥ 6 months\n* Know the participant's memory status and ability to perform activities of daily living\n* Consent to participant\n\nExclusion Criteria:\n\nParticipants\n\n* Resting HR ≤ 50 or ≥ 100 beats\u002Fmin after 5-minutes of quiet resting\n* American College of Sports Medicine contraindications to exercise\n* New, unevaluated symptoms or diseases a healthcare provider has not evaluated\n* Abnormal cardiac condition uncovered during VO2peak testing\n* Enrollment in another intervention that aims at improving cognition\n* Moderate to strenuous exercise ≥150 minutes a week in the previous 6 months\n* ≥ 2 anti-depression medications, or poorly managed or unstable depression\n* Poorly managed or unstable anxiety\n\nStudy partners:\n\n* none",true,"ALL","65 Years",{"count":20,"type":21},216,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to test 6 months of aerobic exercise in older adults who are 65 years or older and have mild cognitive impairment (MCI) or probable\u002Fpossible mild Alzheimer's Disease. The main questions it aims to answer are:\n\n* test the effects of aerobic exercise on aerobic fitness, white matter hyperintensity (WMH) volume, and patient-centered outcomes;\n* identify the best exercise to improve aerobic fitness and reduce non-responses over 6 months; and\n* examines the mechanisms of aerobic exercise's action on memory in older adults with early AD.\n\nParticipants will receive 6 months of supervised exercise, undergo cognitive data collection and exercise testing 5 times over a year span, have an MRI brain scan 3 times over a one-year span, and have monthly follow-up discussions on health and wellness.",[27,28,29,30,31,32],"Mild Cognitive Impairment","Alzheimer Disease","Cognitive Impairment","Cognitive Decline","Memory Loss","Memory Impairment","RECRUITING","2026-05-01",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2023-06-22",{"date":41,"type":21},"2028-06-30",{"name":43,"class":44},"Arizona State University","OTHER",1,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100432111","NCT04906863","Genetic Studies of Early-onset Dementia","Inclusion criteria:\n\n* 35 years and older\n* Individuals experiencing memory concerns or diagnosed with dementia and their family members that are unrelated healthy controls without dementia.\n\nExclusion Criteria:\n\n\\- Individuals with competing diagnosis such as Huntington's disease, traumatic brain injury, drug or alcohol abuse, or schizophrenia, etc., unless family members of a dementia affected individual","35 Years",{"count":53,"type":21},1000,"OBSERVATIONAL","The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease, mild cognitive impairment and other dementias.",[57,58,59,31],"Dementia, Early Onset","Alzheimer Dementia (AD)","Mild Cognitive Impairment (MCI)",[61,62,63,64,65,66,67],"Alzheimer's Disease","Memory loss","Early-onset Alzheimer's disease","Mild cognitive impairment","Normal cognition","Dementia","Genetics","2026-04-24",{"date":70,"type":37},"2026-04-29",{"date":72,"type":37},"2016-09-14",{"date":74,"type":21},"2028-04-30",{"name":76,"class":44},"Columbia University",{"id":78,"slug":4,"hasResults":10,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100560992","NCT06584357","Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia","Bio-Hermes-002","Inclusion Criteria:\n\nPre-screening Inclusion Criteria\n\nParticipants must meet ALL of the following criteria to progress to Visit 1 (Screening):\n\n1. Participant is between 60 to 90 years of age (inclusive) at the time of consent; and\n2. Participant has a study partner who has sufficient and frequent contact with the participant (defined as at least 8 hours of contact a week) and is able to provide accurate information regarding the participant's cognitive and functional abilities.\n\nCore Study Inclusion Criteria\n\nParticipants must meet ALL of the following criteria, in addition to the Pre-screening Inclusion Criteria, for entry into the study:\n\n1. Participants must provide written consent in the IRB-approved or Ethics Committee (EC) approved informed consent form or have a legally authorized representative (LAR) provide written consent on the participant's behalf in accordance with local and national guidance and regulation;\n2. Participants must be willing to undergo an MRI brain scan within 90 days and an amyloid and tau PET scan within 120 days of signing informed consent;\n3. Participants must be willing to comply with all study procedures as outlined in the informed consent, including blood sampling, genetic testing, and storage of biospecimens for future research;\n4. Fluency in the language of the tests used at the study site;\n5. Participants must be willing to be contacted for possible participation in clinical research trials once their participation in this study ends; and\n6. Participants must have a Mini-Mental State Exam (MMSE) score of 16 to 30 inclusive at screening.\n\nExclusion Criteria:\n\nPre-screening Exclusion Criteria\n\nParticipants who meet ANY of the following criteria will not be eligible to progress to Visit 1 (Screening):\n\n1. Participant is unable to undergo amyloid and tau PET scans due to self-reported pregnancy, sensitivity to ligands being used, poor venous access, contraindication to PET, or planned or recent exposure to ionizing radiation that in combination with the planned administration of amyloid radioligand would result in a cumulative exposure that exceeds recommended local guidelines;\n2. Participants who have reported or have a known negative amyloid PET scan in the past 6 months;\n3. Participants with any known contraindication to brain MRI scan;\n4. Participants with history of stroke or seizures within 1 year of the Pre-Screening Visit;\n5. Participants with history of cancer within the past 5 years with the exception of non-melanoma skin cancer or prostate cancer in situ;\n6. Participants with known or suspected alcohol or drug abuse or dependence within 1 year of the Pre- Screening Visit;\n7. Participants who report any current unstable psychiatric symptoms that could interfere with study procedures or impact study data (e.g., uncontrolled depression);\n8. Participants who have received any potential disease modifying AD treatment within 6 months prior to the Pre-screening Visit; and\n9. Participants with known history or self-report to be Human Immunodeficiency Virus (HIV) Positive unless controlled by antiviral medication.\n\nCore Study Exclusion Criteria\n\nParticipants who meet ANY of the following criteria, in addition to the Pre-screening Exclusion Criteria, will not be eligible to enroll into the study:\n\n1. Participants who, in the opinion of the Site Principal Investigator, have serious or unstable medical conditions that would prohibit their completion of all study procedures and data collection;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Participants with self-reported, untreated conditions such as vitamin B12 or folate deficiency or bladder infections that in the opinion of the Site Principal Investigator could contribute to cognitive impairment;\n4. Participants who have completed cognitive testing within 1 month of Visit 1 (Screening) where the Site Principal Investigator believes the participant's exposure may cause practice effect;\n5. Participants who have any neurological disorder affecting the central nervous system, other than AD, that may be contributing to cognitive impairment (e.g., Parkinson's disease, other dementias, multiple concussions or seizures) as deemed significant by the Site Principal Investigator;\n6. Participants with a Geriatric Depression Scale (GDS) score greater than or equal to 8 at Visit 1 (Screening) and is deemed to be clinically significantly depressed by the Site Principal Investigator;\n7. Participants with a Rey Auditory Verbal Learning Test (RAVLT) t-score of ≥ 1.2 standard deviation above the mean. For non-African Americans, calculate age-sex-education adjusted t-scores. For African American participants, use the MOANS to calculate the age-education adjusted t-scores;\n8. Participants weighing less than 110 pounds;\n9. Participants who are direct employees or family members of direct employees of the participating investigators' sites;\n10. Participants who are direct employees of the Sponsor;\n11. Participants who, in the opinion of the investigator, are unable to complete cognitive testing due to inadequate visual or auditory acuity; and\n12. For participants completing the RetiSpec retinal scan: Those with a known history of contraindication or allergy to Tropicamide 1% (pupil dilation drop).\n\nLongitudinal Sub-Study Eligibility\n\nInclusion Criteria:\n\nParticipants must meet ALL of the following criteria for entry into the sub-study:\n\n1. Participants who completed the Bio-Hermes-002 Core Study;\n2. Are willing to complete phone call visits with site staff every three months and return to the clinic for an annual evaluation; and\n3. Are willing to complete annual PET scans for both amyloid and tau scans.\n\nExclusion Criteria:\n\nParticipants who meet ANY of the following criteria will not be eligible for entry into the sub-study:\n\n1. Those who are enrolled or intend to enroll into a clinical trial for Alzheimer's disease with a potential disease-modifying intervention;\n2. Participants who have serious or unstable medical conditions that would likely preclude their participation in an interventional research trial;\n3. Those who intend to use medications outside clinical research studies approved by regulatory authorities to modify Alzheimer's disease pathology.","60 Years","90 Years",{"count":86,"type":21},1200,"Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.",[27,61,89,31,90,32],"Alzheimer's Disease, Early Onset","Memory Disorders",[61,89,27,92,93,31,90,32],"Older Volunteers","Healthy Volunteers","2026-04-13",{"date":96,"type":37},"2026-04-15",{"date":98,"type":37},"2024-09-26",{"date":100,"type":21},"2028-07",{"name":102,"class":103},"GAP Innovations, PBC","INDUSTRY",26,{"id":106,"slug":4,"hasResults":10,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":17,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":123,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100610496","NCT07228338","Cholinergic Enhancement of Theta","Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity","Inclusion Criteria:\n\n1. Age 18 - 75 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n\nExclusion Criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. We note that pregnant patients are excluded from undergoing iEEG.\n3. Hepatic impairment (moderate or severe).\n4. Renal impairment (moderate or severe).\n5. Clinically significant bladder outlet obstruction or incomplete bladder emptying, such as patients with prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention.\n6. History of hypersensitivity to COBENFY or trospium chloride (angioedema risks).\n7. Untreated narrow-angle glaucoma.\n8. Biliary Disease (symptomatic gallstones, gallbladder disorders, pancreatitis).\n9. Strong Inhibitors of CYP2D6 such as fluoxetine, paroxetine, bupropion, terbinafine.\n10. Sensitive Substrates of CYP3A4 such as buspirone, eletriptan.\n11. Narrow Therapeutic Index Substrates of P-glycoprotein such as digoxin, colchicine, apixaban.\n12. Drugs Eliminated by Active Tubular Secretion.\n13. Antimuscarinic Drugs such as diphenhydramine, benztropine, oxybutynin.","18 Years","75 Years",{"count":114,"type":21},50,[116],"EARLY_PHASE1","The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a placebo pill, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal serial recall and\u002For associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.",[119,120,121,122,31],"Epilepsy","Seizures","Cognitive Impairment, Mild","Memory Disorder",[124,125,126],"oscillatory changest","cholinergic agonist","muscarinic agonist","NOT_YET_RECRUITING","2026-04-08",{"date":130,"type":37},"2026-04-09",{"date":132,"type":21},"2026-10",{"date":134,"type":21},"2031-10",{"name":136,"class":44},"University of Texas Southwestern Medical Center",{"id":138,"slug":4,"hasResults":10,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":16,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":45},"100329821","NCT03574207","Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities","The investigators anticipate enrolling 48 subjects total:\n\n* 16 healthy young adults (age 19-35)\n* 16 healthy older adults (demographically matched to aMCI group for age, sex, and educational attainment)\n* 16 older adults diagnosed with amnestic mild cognitive impairment (aMCI)\n\nInclusion Criteria:\n\n1. Adults 19 years of age and older\n2. Healthy adults without history of psychiatric or neurological disease OR previous diagnosis of amnestic MCI\n3. Must be able to provide informed consent\n4. Must have the ability to comply with basic instructions and have the ability to sit comfortably still for TMS, neuroimaging, and other study procedures.\n5. Right-handed based on self-report (pre-screening) and evaluation with a standard test.\n\nExclusion Criteria:\n\n1. Individuals who have ferrous metal implanted in their body (other than in their teeth) or any other non-removable medical and\u002For metallic implant\n2. Individuals who have increased intracranial pressure\n3. Individuals who have any major medical illness (e.g., cancer, HIV+, hepatitis, heart disease)\n4. Individuals who have confounding\u002Fdual diagnoses (e.g., comorbid mental illness and substance use disorder)\n5. Individuals with current diagnoses of alcohol or substance abuse\u002Fdependence\n6. Individuals with epilepsy, any history of seizures, or using medication that lowers seizure threshold\n7. Individuals with any neurological disorder other than aMCI (e.g., stroke, traumatic brain injury)\n8. Pregnant females --- as determined by urine pregnancy test --- will be excluded from this study due to uncertainty of the effects of MRI and TMS on the fetus\n9. Not right-handed based on self-report (pre-screening) or evaluation with a standard test\n10. Not a native English speaker.","19 Years",{"count":144,"type":21},80,[24],"This is a pilot study of non-invasive transcranial magnetic stimulation (TMS) to improve memory in healthy adults. It will also examine treating memory deficits in older adults with amnestic mild cognitive impairment (aMCI), a condition that frequently precedes Alzheimer's disease (AD). The study will test whether a form of non-invasive brain stimulation repetitive transcranial magnetic stimulation (rTMS) can improve memory abilities in healthy young adults, healthy older adults, and older adults with aMCI by retuning memory-related brain networks. This study is a key first step which will support the long-term goal of treating memory deficits in neurological patients. It is expected that rTMS will improve memory abilities in all participants, and that the improvements in memory will be attributable to changes in the connectivity of memory-related brain networks.",[27,31],"2026-03-23",{"date":150,"type":37},"2026-03-25",{"date":152,"type":37},"2019-01-01",{"date":154,"type":21},"2027-12",{"name":156,"class":44},"University of Nebraska",{"id":158,"slug":4,"hasResults":10,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":10,"sex":17,"minAge":164,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100490050","NCT05661084","Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia","Multifocal Transcranial Current Stimulation for Cognitive and Motor Dysfunction in Dementia","ACDCStim","Inclusion Criteria:\n\nParticipants (Ps)\n\n* willing and capable to give informed consent for the participation in the study after it has been thoroughly explained\n* able and willing to comply with all study requirements\n* an informed consent form was signed\n* able to read, write, and communicate in English\n\nCaregiver\u002FAdministrators (As)\n\n* at least 18 years of age\n* able to read, write, and communicate in English\n* self-reported computer proficiency and willingness to learn how to use tES as defined by \"yes\" answers to the questions \"Do you feel comfortable using a computer?\" and \"Are you willing to be the primary caregiver for a participant and learn how to administer tES?\"\n* stated availability during weekdays throughout the study period to administer tES to the Ps\n\nExclusion Criteria:\n\nParticipants (Ps)\n\n* major psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis\n* blindness or other disabilities that prevent task performance\n* contraindications to tES, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, etc.)\n* the presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen\n* an inability to understand study procedures following review of the Informed Consent form\n* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator\n\nCaregiver\u002FAdministrators (As)\n\n* mild cognitive impairment defined by a MoCA score ≤26 during the in-person screen\n* insufficient understanding of study procedures following review of the Informed Consent form\n* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.\n* poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tES","55 Years",{"count":166,"type":21},144,[24],"This project aims to examine the efficacy of remote, caregiver-led tES\u002Fbrain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.",[66,31,28,170,171],"Executive Dysfunction","Mobility Limitation",[61,66,173,174,175,176,177,178],"Memory","Brain Stimulation","transcranial alternating current stimulation (tACS)","transcranial direct current stimulation (tDCS)","Executive function","instrumental activities of daily living (IADL)","2026-01-08",{"date":181,"type":37},"2026-01-12",{"date":183,"type":37},"2023-01-24",{"date":185,"type":21},"2027-08-31",{"name":187,"class":44},"Hebrew SeniorLife",{"id":189,"slug":4,"hasResults":10,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":16,"sex":17,"minAge":111,"maxAge":164,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":45},"100484896","NCT05594017","Pharmacological Modulation of Brain Oscillations in Memory Processing","Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe","Patient inclusion criteria:\n\n1. Age 18 - 55 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n5. Body mass index between 18-35 kg\u002Fm2.\n\nPatient exclusion criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. Note that pregnant patients are excluded from undergoing iEEG generally and all patients undergo a positive screening urine test for drugs of abuse at screening: cannabinoids, cocaine, amphetamines, barbiturates, opiates not otherwise explained by their prescribed medications.\n3. History of renal insufficiency.\n4. Unstable cardiac syndrome or active cardiac symptoms.\n5. Patients with liver failure.\n6. Patients with BPH.\n7. Patients with autoimmune neuropathy.\n8. Patients with uncontrolled hyperthyroidism.\n9. Patients with a history of dementia.\n10. Patient with a history of delirium after using transdermal scopolamine.\n11. History of narrow-angle glaucoma.\n12. History of pyloric obstruction or paralytic ileus.\n13. History of myasthenia gravis, obstructive uropathy, porphyria, or myasthenia gravis.",{"count":195,"type":21},60,[116],"The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and\u002For spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.",[119,120,121,90,31],[200,201,202],"oscillatory changes","cholinergic antagonist","muscarinic antagonist","2025-09-29",{"date":205,"type":37},"2025-10-03",{"date":207,"type":37},"2019-08-01",{"date":209,"type":21},"2027-05-31",{"name":136,"class":44},{"id":212,"slug":4,"hasResults":10,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":10,"sex":17,"minAge":216,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100601804","NCT07115251","Plans4Care: Personalized Dementia Care on Demand","Inclusion Criteria:\n\n1. A family, friend, or neighbor who self-identifies as having primary care responsibilities for a person with memory loss;\n2. \\>21 years of age;\n3. Able to use an internet capable device (computer, tablet or smart phone), and have stable internet access;\n\n6\\. Actively (e.g., past 6 months) managing a dementia-related care challenge.","21 Years",{"count":218,"type":21},160,[220],"PHASE2","The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms (anxiety, agitation), functional changes and other concerns, and receive an action plan which provides easy-to-use non-drug strategies, resources, tips and education.\n\nThe goal of the study is to evaluate whether using the Plans4Care app will help you feel more confident providing care to your family member with dementia, better understand dementia, and enhance your own well-being. You also have the option to talk with a care advisor who can practice use of strategies or address concerns you may have.",[66,223,58,31],"Dementia Alzheimer Type",[225],"Caregiver, Dementia, Memory Loss, Alzheimer","2025-08-04",{"date":228,"type":37},"2025-08-11",{"date":230,"type":21},"2025-08-30",{"date":232,"type":21},"2027-09-30",{"name":234,"class":103},"Plans4Care Inc",{"id":236,"slug":4,"hasResults":10,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":16,"sex":17,"minAge":111,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":45},"100493852","NCT05710549","Understanding Brain Mechanisms Involved in Autobiographical Memory","Understanding Brain Mechanisms Involved in Autobiographical Memory Using High-density Electroencephalography and Transcranial Alternating Current Stimulation","Inclusion Criteria:\n\nCognitively-Unimpaired Younger and Older Adults\n\n* Age 18 to 35 years old (younger adults)\n* Age 55+ years old (older adults)\n* without any cognitive impairment (based on the Montreal Cognitive Assessment: MoCA)\n* willing and capable to give informed consent for participation in the study after it has been thoroughly explained able\n* willing to comply with all study requirements informed consent form was signed\n\nMild Cognitive Impairment (MCI) patients\n\n* Age 55+ years old\n* Clinical Diagnosis of MCI\n* Confirmation of diagnosis will be made by the study MD based on a holistic consideration of the participant's cognitive evaluation and history\n* Mini-Mental State Examination (MMSE) ≥ 18 (Mild AD ≥ 21)\n* CDR ≥ .5\n* Demonstration or history of autobiographical memory impairments\n* On a stable dose of medications for memory loss including cholinesterase inhibitors (e.g. donepezil, rivastigmine) or memantine as defined as 6 consecutive weeks of treatment at an unchanging dose\n* Minimum of completed 8th-grade education\n* willing and capable to give informed consent for participation in the study after it has been thoroughly explained - note that to ensure this in the case of the MCI participants, a cut-off of MOCA score \\>18 will be applied\n* able and willing to comply with all study requirements informed consent form was signed\n\nExclusion Criteria:\n\nCognitively-Unimpaired Younger and Older Adults\n\n* any cognitive impairment captured by the Montreal Cognitive Assessment (MoCA) - score \\\u003C 26\n* major psychiatric co-morbidity including major depressive disorder, schizophrenia, or psychosis\n* blindness or other disabilities that prevent task performance\n* Contraindication for undergoing MRI\n* Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)\n\nMild Cognitive Impairment (MCI) patients\n\n* Age \\\u003C 55 years old\n* Any current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder)\n* Other than MCI, any history of other progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tubular sclerosis) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions\n* History of head trauma resulting in prolonged loss of consciousness\n* Current history of poorly controlled headaches including chronic medication for migraine prevention\n* History of fainting spells of unknown or undetermined etiology that might constitute seizures\n* History of seizures, diagnosis of epilepsy, or immediate (1st-degree relative) family history of epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Any unstable medical condition or chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) or study complication\n* contraindications to tACS, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp\n* Contraindication for undergoing MRI or receiving tACS\n* Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement)\n* Any devices such as a pacemaker, medication pump, nerve stimulator, TENS unit, ventriculoperitoneal shunt unless cleared by the responsible covering MD","85 Years",{"count":243,"type":21},120,[24],"The overall objective of this project is to characterize the spatiotemporal dynamics of brain oscillations underpinning autobiographical memory (ABM) and the modulation of the memory network using non-invasive brain stimulation.",[27,28,31],[248,249,250,251,175],"autobiographical memory (ABM)","high-density electroencephalography (EEG)","magnetic resonance imaging (MRI)","non-invasive brain stimulation (NIBS)","2025-07-09",{"date":254,"type":37},"2025-07-15",{"date":256,"type":37},"2022-04-25",{"date":258,"type":21},"2027-08-01",{"name":260,"class":44},"Lucie Bréchet",{"id":262,"slug":4,"hasResults":10,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":16,"sex":17,"minAge":267,"maxAge":241,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":279,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":45},"100525638","NCT06124339","Brain Health Virtual Reality Study","Interventions to Promote Brain Health Virtual Reality Study","Inclusion Criteria:\n\n1. 50-85 years of age\n2. Fluent in English\n3. Can safely ride a stationary bike\n\nExclusion Criteria:\n\n1. Dementia\n2. History of a neurological disorder\n3. Severe sensory deficits\n4. Inability to perform intervention (e.g., inability to cycle safely)\n5. Contraindications to MRI scan (e.g., pacemaker)\n6. Fear of needles\u002F blood\n7. Prior history of fainting due to sight of needles of blood","50 Years",{"count":269,"type":21},150,[24],"The Interventions for Brain Health Virtual Reality Study is a NIH-funded clinical research trial at the University of California San Diego (UCSD) Health under the supervision of the study principal investigator Dr. Judy Pa. The overarching goal of this trial is to use a novel virtual reality (VR) based intervention that simultaneously engages physical and cognitive activity aimed at improving brain health and cognition in older adults. The investigators will compare 3 types of interventions: physical activity, VR cognitive activity, and combined VR physical and cognitive activity over 16 weeks to evaluate physical and brain health changes.",[273,274,31,32,275,276,90,27,30,277,278],"Aging","Aging Problems","Memory Disorders in Old Age","Memory Disorder, Spatial","Cognitive Change","Cognition Disorders in Old Age",[280,281,282,283,284,285,286,287],"Virtual Reality","technology","intervention","exercise","cycling","memory","brain health","aging","2024-07-08",{"date":290,"type":37},"2024-07-10",{"date":292,"type":37},"2023-08-08",{"date":294,"type":21},"2029-02-01",{"name":296,"class":44},"University of California, San Diego",""]